In addition, data on suicide risk in patients on incretin therapies may be confounded by underlying conditions, including obesity and diabetes, which have been linked to increased suicide risk
There are two primary incretin hormones
Follow-up Repeat metabolic markers after 4-12 weeks, with closer review during dose escalation or major appetite changes
For those who require maximal weight loss, such as people managing severe obesity alongside cardiovascular risk or obstructive sleep apnoea, injectable therapy may remain the medically preferred route
This transition happens relatively quicklyoften within 2-4 weeksbecause your digestive system and brain hunger centers no longer have the chemical brake that tirzepatide provided
Most experts agree that 0.5 to 2.0 pounds per week, or roughly 1% of body weight, is appropriate